Eugenia Carrillo Selected Research

Infections

1/2023	Immunosuppressants alter the immune response associated with Glucantime® treatment for Leishmania infantum infection in a mouse model.
1/2022	An exploratory analysis of C-X-C motif chemokine ligand 10 as a new biomarker of asymptomatic Leishmania infantum infection in solid-organ transplant recipients.
10/2021	Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE Adjuvant.
1/2021	Effect of immunosuppressants on the parasite load developed in, and immune response to, visceral leishmaniasis: A comparative study in a mouse model.
1/2020	Role of asymptomatic and symptomatic humans as reservoirs of visceral leishmaniasis in a Mediterranean context.
5/2019	Prevalence of asymptomatic Leishmania infection and associated risk factors, after an outbreak in the south-western Madrid region, Spain, 2015.
1/2018	Antigenicity of Leishmania-Activated C-Kinase Antigen (LACK) in Human Peripheral Blood Mononuclear Cells, and Protective Effect of Prime-Boost Vaccination With pCI-neo-LACK Plus Attenuated LACK-Expressing Vaccinia Viruses in Hamsters.
11/2017	Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis.
4/2016	Impact of Helminth Infection on the Clinical and Microbiological Presentation of Chagas Diseases in Chronically Infected Patients.
1/2016	Interleukin-27 Early Impacts Leishmania infantum Infection in Mice and Correlates with Active Visceral Disease in Humans.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eugenia Carrillo Research Topics

Disease

21	Visceral Leishmaniasis (Kala Azar) 05/2024 - 03/2008
19	Leishmaniasis 01/2022 - 07/2010
18	Infections 01/2023 - 11/2008
4	Asymptomatic Infections 01/2022 - 11/2008
2	Fever (Fevers) 01/2023 - 07/2019
2	Cutaneous Leishmaniasis 01/2018 - 01/2017
1	Necrosis 01/2021
1	Autoimmune Diseases (Autoimmune Disease) 01/2021
1	Asymptomatic Diseases 01/2020
1	Acanthamoeba Keratitis 01/2018
1	Dry Eye Syndromes (Dry Eye Syndrome) 01/2018
1	Amebiasis (Amoebiasis) 01/2018
1	Coinfection 12/2016
1	Inflammation (Inflammations) 01/2016
1	Malnutrition (Nutritional Deficiencies) 01/2014

Drug/Important Bio-Agent (IBA)

12	AntigensIBA 01/2022 - 03/2008
10	CytokinesIBA 01/2022 - 03/2009
9	VaccinesIBA 10/2021 - 03/2008
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2010
4	Immunosuppressive Agents (Immunosuppressants)IBA 01/2023 - 07/2019
4	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 04/2016
3	Interleukin-2 (IL2)IBA 05/2019 - 01/2017
3	Proteins (Proteins, Gene)FDA Link 01/2018 - 11/2008
2	Nucleic AcidsIBA 05/2024 - 01/2018
2	ElementsIBA 01/2022 - 01/2020
2	Combined VaccinesIBA 10/2021 - 11/2017
2	AntibodiesIBA 01/2021 - 11/2008
2	Recombinant ProteinsIBA 11/2017 - 11/2008
2	Leishmaniasis VaccinesIBA 11/2017 - 10/2014
2	N-Glycosyl HydrolasesIBA 01/2017 - 01/2017
2	EpitopesIBA 01/2017 - 01/2017
2	Immunoglobulin G (IgG)IBA 01/2017 - 04/2016
1	KynurenineIBA 01/2023
1	LigandsIBA 01/2022
1	ChemokinesIBA 01/2022
1	glucopyranosyl lipid-AIBA 10/2021
1	VirosomesIBA 10/2021
1	GenieIBA 03/2021
1	tetrahydrozoline (Visine)FDA Link 03/2021
1	Methotrexate (Mexate)FDA LinkGeneric 01/2021
1	Methylprednisolone FDA LinkGeneric 01/2021
1	Ferritins (Ferritin)IBA 07/2019
1	Phosphotransferases (Kinase)IBA 01/2018
1	Lubricant Eye Drops (Artificial Tears)IBA 01/2018
1	Interleukin-17 (Interleukin 17)IBA 01/2017
1	InsecticidesIBA 01/2016
1	Interleukin-27 (Interleukin 27)IBA 01/2016
1	Messenger RNA (mRNA)IBA 01/2016
1	Interleukin-10 (Interleukin 10)IBA 01/2016
1	Surface Antigens (Surface Antigen)IBA 01/2014
1	tryparedoxin peroxidaseIBA 11/2008

Therapy/Procedure

1	Contact Lenses 01/2018
1	Transplantation 01/2017
1	Highly Active Antiretroviral Therapy (HAART) 12/2016
1	Protein-Restricted Diet (Diet, Protein Restricted) 01/2014